Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AORTNASDAQ:LQDANASDAQ:SMLRNASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$29.77+3.6%$26.83$21.97▼$32.33$1.21B1.62335,006 shs396,113 shsLQDALiquidia Technologies$13.59-3.5%$15.22$8.26▼$19.41$1.20B0.041.21 million shs2.36 million shsSMLRSemler Scientific$28.53-6.5%$35.40$21.77▼$81.56$329.86M1.42510,527 shs1.04 million shsTNDMTandem Diabetes Care$20.07+0.1%$20.06$15.75▼$48.24$1.38B1.521.49 million shs1.18 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion+3.80%+1.76%+1.05%+21.97%+28.49%LQDALiquidia Technologies-3.55%-9.28%-28.02%-8.91%+1.95%SMLRSemler Scientific-6.52%-9.43%-30.21%-28.75%-26.18%TNDMTandem Diabetes Care+0.15%-10.56%-13.04%-2.67%-53.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORTArtivion2.551 of 5 stars1.65.00.00.02.62.51.9LQDALiquidia3.7055 of 5 stars4.51.00.00.03.14.20.6SMLRSemler Scientific2.783 of 5 stars3.52.00.00.01.82.51.3TNDMTandem Diabetes Care4.0991 of 5 stars4.21.00.04.92.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORTArtivion 3.14Buy$32.007.49% UpsideLQDALiquidia Technologies 3.00Buy$26.8997.86% UpsideSMLRSemler Scientific 3.00Buy$71.00148.86% UpsideTNDMTandem Diabetes Care 2.40Hold$33.4366.56% UpsideCurrent Analyst Ratings BreakdownLatest SMLR, TNDM, AORT, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025AORTArtivionCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.006/16/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$24.006/12/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.006/11/2025LQDALiquidia TechnologiesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $23.006/2/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025LQDALiquidia TechnologiesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.005/28/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.005/28/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025LQDALiquidia TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $35.005/27/2025LQDALiquidia TechnologiesBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORTArtivion$388.54M3.27$0.88 per share33.86$6.59 per share4.52LQDALiquidia Technologies$14.14M82.14N/AN/A$0.91 per share14.93SMLRSemler Scientific$56.29M5.65$4.32 per share6.61$24.90 per share1.15TNDMTandem Diabetes Care$940.20M1.42N/AN/A$4.01 per share5.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORTArtivion-$13.36M-$0.50N/A59.54N/A-5.49%3.63%1.34%8/6/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)SMLRSemler Scientific$40.90M-$2.61N/A∞N/A-60.69%19.75%15.47%8/4/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%7/30/2025 (Estimated)Latest SMLR, TNDM, AORT, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SMLRSemler ScientificN/A-$0.76N/A-$6.74N/A$8.84 million5/8/2025Q1 2025LQDALiquidia Technologies-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million5/5/2025Q1 2025AORTArtivion$0.12$0.06-$0.06-$0.01$94.81 million$98.98 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million3/19/2025Q4 2024LQDALiquidia Technologies-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORTArtivionN/AN/AN/AN/AN/ALQDALiquidia TechnologiesN/AN/AN/AN/AN/ASMLRSemler ScientificN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORTArtivion0.711.881.33LQDALiquidiaN/A6.336.33SMLRSemler ScientificN/A3.143.09TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORTArtivion86.37%LQDALiquidia Technologies64.54%SMLRSemler Scientific49.37%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipAORTArtivion8.10%LQDALiquidia Technologies30.10%SMLRSemler Scientific30.20%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORTArtivion1,60042.70 million39.24 millionOptionableLQDALiquidia Technologies5085.49 million59.75 millionOptionableSMLRSemler Scientific12011.15 million7.78 millionNot OptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableSMLR, TNDM, AORT, and LQDA HeadlinesRecent News About These CompaniesChicago Capital LLC Has $397,000 Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 18 at 4:41 AM | marketbeat.comGAMMA Investing LLC Increases Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 18 at 3:13 AM | marketbeat.comTruist Financial Initiates Coverage on Tandem Diabetes Care (NASDAQ:TNDM)June 18 at 1:57 AM | americanbankingnews.comTruist Financial Begins Coverage on Tandem Diabetes Care (NASDAQ:TNDM)June 16 at 8:37 AM | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Trading Down 4.4% - Here's WhyJune 12, 2025 | marketbeat.comAbbott to pair glucose-ketone sensor with Tandem's insulin pumpsJune 10, 2025 | modernhealthcare.comTandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitorJune 10, 2025 | drugdeliverybusiness.comTandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 7.1% - Should You Buy?June 10, 2025 | marketbeat.comTandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone SensorJune 10, 2025 | finance.yahoo.comTandem Diabetes Care (NASDAQ:TNDM) Upgraded at Wall Street ZenJune 9, 2025 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Upgraded by Wall Street Zen to Hold RatingJune 7, 2025 | marketbeat.comTandem Diabetes Care: A Barbell Bet On A High-Stakes TurnaroundJune 5, 2025 | seekingalpha.comTandem Diabetes at Jefferies: Expanding Market HorizonsJune 4, 2025 | investing.comDo You Believe in the Long-Term Growth Potential of Tandem Diabetes Care (TNDM)?June 4, 2025 | insidermonkey.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 3, 2025 | marketbeat.comJefferies Financial Group Inc. Has $330,000 Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 1, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of "Hold" from AnalystsJune 1, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Trading Down 6.2% - Time to Sell?May 31, 2025 | marketbeat.comTandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue?May 30, 2025 | zacks.comTandem agrees to pay $36M to settle Roche patent litigationMay 29, 2025 | drugdeliverybusiness.comReflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM)May 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMLR, TNDM, AORT, and LQDA Company DescriptionsArtivion NYSE:AORT$29.77 +1.04 (+3.62%) Closing price 06/17/2025 03:59 PM EasternExtended Trading$29.79 +0.02 (+0.07%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Liquidia Technologies NASDAQ:LQDA$13.59 -0.50 (-3.55%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$13.78 +0.19 (+1.36%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Semler Scientific NASDAQ:SMLR$28.53 -1.99 (-6.52%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$29.00 +0.47 (+1.66%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.Tandem Diabetes Care NASDAQ:TNDM$20.07 +0.03 (+0.15%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$20.31 +0.24 (+1.20%) As of 06:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? Can Luckin and Dutch Bros Take Market Share From Starbucks? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
